VLN4

VLN4 is a discovery-stage antibody-drug conjugate (ADC) being developed by Valink Therapeutics for oncology applications. It is engineered as a bispecific or multispecific ADC using the company's proprietary LiliumX™ discovery platform and V-gate™ approach. The molecule is designed to deliver a cytotoxic payload specifically to tumor cells, aiming to improve upon the therapeutic index and precision of traditional monospecific ADCs. As of early 2024, the specific molecular targets and the primary cancer indications for VLN4 remain unannounced, though it is part of a pipeline focused on next-generation biologics for solid tumors and pan-cancer applications.